Pneuma Respiratory

Executive Summary

Pneuma Respiratory is a private company headquartered in Durham, North Carolina, focused on revolutionizing respiratory drug delivery through its precision aerosol technology. The platform generates sub-micron droplets, enabling targeted delivery of pharmaceuticals and reduced-risk nicotine solutions directly to the lungs. Founded in 2015, the company aims to address significant unmet needs in respiratory diseases such as asthma, COPD, and pulmonary infections, as well as provide safer alternatives for nicotine consumption. Pneuma's technology differentiates itself by achieving higher lung deposition efficiency and more consistent dosing compared to conventional inhalers, potentially improving patient outcomes and reducing systemic side effects. The company's mission is to save lives by advancing inhalation therapy. Pneuma operates in the drug delivery space with a focus on both therapeutic and consumer health applications. While still in the early stages without disclosed clinical pipelines, the company's proprietary platform has attracted interest from pharmaceutical partners seeking to reformulate existing drugs for inhalation. The reduced-risk nicotine segment presents a large market opportunity amid global tobacco harm reduction efforts. Key risks include regulatory hurdles, competition from established inhaler manufacturers, and the need for substantial capital to fund development. With a strong intellectual property portfolio and a seasoned management team, Pneuma is positioned to become a leader in precision respiratory delivery if it can secure strategic partnerships and navigate clinical validation successfully.

Upcoming Catalysts (preview)

• Q3 2026Partnership with major pharma for inhaled antibiotic delivery60% success
• Q4 2026Series B funding round to support clinical development70% success